购物车
- 全部删除
- 您的购物车当前为空
Gefitinib (ZD1839) 是一种 EGFR 一代抑制剂,具有口服活性,抑制 EGFR 19 Del 和 L858R 突变。Gefitinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。Gefitinib 用药会产生 EGFR C797S 耐药突变。
Gefitinib (ZD1839) 是一种 EGFR 一代抑制剂,具有口服活性,抑制 EGFR 19 Del 和 L858R 突变。Gefitinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。Gefitinib 用药会产生 EGFR C797S 耐药突变。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50 mg | ¥ 163.5¥ 327 | 现货 | |
100 mg | ¥ 230¥ 460 | 现货 | |
500 mg | ¥ 399¥ 798 | 现货 | |
1 g | ¥ 589¥ 1,178 | 现货 | |
5 g | ¥ 1,180.5¥ 2,361 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 248.5¥ 497 | 现货 |
产品描述 | Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation. |
靶点活性 | Tyr1173:26 nM (NR6W cells), Tyr1173:37 nM (NR6wtEGFR cells), Tyr992:37 nM (NR6wtEGFR cells) , Tyr992:57 nM (NR6W cells) |
体外活性 | 方法:23 种肿瘤细胞用 Gefitinib 处理 72 h,使用 MTT 方法检测细胞活力。
结果:只有 PC9 细胞系的 IC50<1 μmol/L (高度敏感),14 个细胞系的 IC50>10 μmol/L (抗性),其余 8 个细胞系具有 1-10 μmol/L 的 IC50 (中等敏感)。[1] 方法:肿瘤细胞 HT29、KB、Du145 和 A549 用 Gefitinib (0.032-50 μM) 处理 2 h,在细胞裂解前五分钟加入 EGF (0.1 μg/mL),使用 Western Blot 方法检测靶点蛋白表达水平。 结果:Gefitinib 在所有肿瘤细胞系中产生 EGFR 自磷酸化的剂量依赖性抑制。[2] |
体内活性 | 方法:为检测体内抗肿瘤活性,将 Gefitinib (3.125-200 mg/kg in 0.5% polysorbate 80) 口服给药给携带肿瘤 A431、 Du145 或 A549 的 nude 小鼠,每天一次,持续七-十五天。
结果:Gefitinib 剂量依赖性方式抑制 A431、 Du145 或 A549 肿瘤生长。[2] 方法:为检测体内抗肿瘤活性,将 Gefitinib (40 mg/kg,每天一次) 或 Gefitinib (200 mg/kg,每五天一次) 灌胃给药给携带人肺癌肿瘤 H3255 的 athymic nude 小鼠,持续两周。 结果:每周治疗显示出比每天治疗更好的抑制作用。与每日给药方案相比,每周给药方案对 p-EGFR、p-ERK 和 p-AKT 的抑制作用更强。[3] |
细胞实验 | The human NSCLC H1299, H1975, A549, H460, GLC82, H460, and CALU-3 cell lines were provided by the American Type Culture Collection and maintained in RPMI-1640 supplemented with 10% FBS in a humidified atmosphere with 5% CO2. CALU-3 GEF-R is a cell line obtained in vitro as previously described. Briefly, over a period of 12 months, human CALU-3 lung adenocarcinoma cells were continuously exposed to increasing concentrations of gefitinib. The starting dose was the dose causing the inhibition of 50% of cancer cell growth (IC50; gefitinib, 1 μmol/L). The drug dose was progressively increased to 15 μmol/L in approximately 2 months, to 20 μmol/L after other 2 months, to 25 μmol/L after additional 2 months, and, finally, to 30 μmol/L for a total of 12 months. The established resistant cancer cell lines were then maintained in continuous culture with the maximally achieved dose of each TKI that allowed cellular proliferation (30 μmol/L for each drug) [2]. |
动物实验 | Four- to 6-week old female balb/c athymic (nu+/nu+) mice were purchased from Charles River Laboratories. Mice were acclimatized for 1 week before being injected with cancer cells and injected subcutaneously with 107 H1299 and CALU-3 GEF-R cells that had been resuspended in 200 μL of Matrigel. When established tumors of approximately 75 mm3 in diameter were detected, mice were left untreated or treated with oral administrations of metformin (200 mg/mL metformin diluted in drinking water and present throughout the experiment), gefitinib (150 mg/kg daily orally by gavage), or both for the indicated time periods. Each treatment group consisted of 10 mice. Tumor volume was measured using the formula π/6 × larger diameter × (smaller diameter)2. Tumor tissues were collected from the xenografts and analyzed by Western blotting for the expression and activation of EGFR, AMPK, mitogen-activated protein kinase (MAPK), and S6 [2]. |
别名 | 吉非替尼, ZD1839 |
分子量 | 446.9 |
分子式 | C22H24ClFN4O3 |
CAS No. | 184475-35-2 |
Smiles | N(C=1C2=C(C=C(OC)C(OCCCN3CCOCC3)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4 |
密度 | 1.322g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | DMSO: 18.33 mg/mL (41.02 mM) Ethanol: 4.5 mg/mL (10 mM) 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.47 mg/mL (10 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
|
中药材名称 | 中药材拉丁名 | 性 | 味 | 归经 |
---|---|---|---|---|
雷公藤 | Tripterygium wilfordii Hook. f. | 凉 | 辛, 苦 | 心, 肝 |
中成药名称 | 处方组成 | 中成药类型 |
---|---|---|
雷公藤片 | 雷公藤 | 清热药 |
金关片 | 雷公藤,续断,山药,细辛,制附子,茯苓,桑枝,桂枝,鹿角霜,秦艽,丹参,枸杞子,牛膝,鸡血藤,黄精,淫羊藿,薏苡仁,黄芪 | 扶正药 |
方剂名称 | 处方组成 | 剂型 | 处方来源 |
---|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容